Laurion Capital Management LP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 116 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
Laurion Capital Management LP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$1,341,036
-51.6%
1,136,471
-42.2%
0.01%
-50.0%
Q2 2023$2,772,408
-22.3%
1,966,247
-17.3%
0.02%
-33.3%
Q1 2023$3,566,910
+28.2%
2,377,9400.0%0.02%
+84.6%
Q4 2022$2,782,190
+3.5%
2,377,9400.0%0.01%
-18.8%
Q3 2022$2,687,000
-29.8%
2,377,940
-1.8%
0.02%
-72.9%
Q2 2022$3,827,000
+34690.9%
2,422,367
+19316.2%
0.06%
Q2 2020$11,00012,4760.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2023
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders